WhiteOak Capital Pharma and Healthcare Fund Direct Growth

WhiteOak Capital Pharma and Healthcare Fund Direct Growth

Equity

Direct

Sector - Healthcare

NAV as on 21-02-2025

₹ 12.38

▲0.6%

1D

Inception Returns

24.6%

/yr

About WhiteOak Capital Pharma and Healthcare Fund Direct Growth

WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 6 February, 2024. The fund is managed by Piyush Baranwal. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. WhiteOak Capital Pharma and Healthcare Fund Direct Growth has ₹286 Cr worth of assets under management (AUM) as on Jan 2025 and is less than category average.
  2. The fund has an expense ratio 0.7.

Returns

WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 24.57% since inception. Over the last 1 year the fund has given a CAGR return of 23.98%.

Holdings

WhiteOak Capital Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Max Healthcare Institute Ltd Ordinary Shares, Divi's Laboratories Ltd, Lupin Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

Investment objective of WhiteOak Capital Pharma and Healthcare Fund Direct Growth

The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 500.00 and for SIP is INR 100.00. WhiteOak Capital Pharma and Healthcare Fund Direct Growth has no lock in period.

Historical NAV & Returns

Absolute
▲
▼

zero opening, trading, fund transfer fee
546 people have invested ₹ 25.1L in WhiteOak Capital Pharma and Healthcare Fund Direct Growth in the last three months

WhiteOak Capital Pharma and Healthcare Fund Direct Growth Overview

Expense ratio0.68%
Benchmark
S&P BSE Healthcare PR
AUM₹286 Cr
Inception Date6 February, 2024
Min Lumpsum/SIP₹500/₹100
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
73.27%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

Trailing Returns

as on (21-Feb-25)

Period
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
-6.2%
-2.8%
-6.3%
3M
-2.7%
-4.5%
-4.8%
6M
3.1%
-10.9%
-4.5%
1Y
24%
3.5%
12.5%

Fund Distribution

as on (31-Jan-25)

  • Equity 92.3%

  • Debt & Cash 7.7%

Small cap
31.6%
Mid cap
29.7%
Large cap
26.3%
Sector Allocation

Jan'25

Dec'24

Nov'24

Health
95.4%
Basic Materials
4.1%
Financial Services
0.5%
All changes are between Nov'24 and Jan'25
Dec'24
Nov'24
Fund Returns
4.11%
0.81%
Nifty 500
-2.02%
-0.60%
Parameters
Jan'25
Dec'24
Nov'24
AUM
₹ 282.6 Cr
₹ 254.1 Cr
₹ 232 Cr
  • AUM of the fund stands at 282.6 Cr as of Jan'25
  • AUM increased by 28.5 Cr between Jan'25 and Dec'24
Top Stocks bought last month
Max Healthcare Institute Ltd Ordinary Shares's allocation increased from 4.9% to 6.93%
Max Healthcare Institute Ltd Ordinary Shares's allocation increased from 4.9% to 6.93%
Sun Pharmaceuticals Industries Ltd's allocation increased from 8.9% to 10.33%
Sun Pharmaceuticals Industries Ltd's allocation increased from 8.9% to 10.33%
Cipla Ltd's allocation increased from 5.72% to 7%
Cipla Ltd's allocation increased from 5.72% to 7%
Top Stocks sold last month
Divi's Laboratories Ltd's allocation decreased from 6.26 % to 6.18 %
Divi's Laboratories Ltd's allocation decreased from 6.26 % to 6.18 %
Laurus Labs Ltd's allocation decreased from 2.39 % to 2.18 %
Laurus Labs Ltd's allocation decreased from 2.39 % to 2.18 %
Ipca Laboratories Ltd's allocation decreased from 2.38 % to 2.1 %
Ipca Laboratories Ltd's allocation decreased from 2.38 % to 2.1 %
Large Cap allocation has gone down from 29.5% to 26.3%
Large Cap allocation has gone down from 29.5% to 26.3%
Small Cap allocation has gone up from 28.9% to 31.6%
Small Cap allocation has gone up from 28.9% to 31.6%
Mid Cap allocation has gone up from 25.5% to 29.7%
Mid Cap allocation has gone up from 25.5% to 29.7%
Cash allocation has gone down from 12.2% to 7.7%
Cash allocation has gone down from 12.2% to 7.7%

Top 3 Sectors in January were Health, Basic Materials & Financial Services

Jan'25
Health
95%
Basic Materials
4%
Financial Services
Dec'24
Health
95%
Basic Materials
3%
Financial Services
1%

  • Equity

  • Debt & Cash

Holdings
Weight%
1M Change
Sun Pharmaceuticals Industries Ltd
Sun Pharmaceuticals Industries Ltd
10.33%
27%
Cipla Ltd
Cipla Ltd
7%
27.9%
Max Healthcare Institute Ltd Ordinary Shares
Max Healthcare Institute Ltd Ordinary Shares
6.93%
52.2%
Divi's Laboratories Ltd
Divi's Laboratories Ltd
6.18%
9.2%
Lupin Ltd
Lupin Ltd
4.95%
15.6%
See all

  • Returns %

  • Fund Ratios

  • Overview

Funds
1Y Returns
3Y Returns
5Y Returns
Since Inception
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
23.98%
-
-
24.57%
DSP Healthcare Fund Direct Growth
DSP Healthcare Fund Direct Growth
16.81%
22.84%
26.84%
25.75%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
16.76%
23.75%
27.02%
22.21%
SBI Healthcare Opportunities Fund Direct Growth
SBI Healthcare Opportunities Fund Direct Growth
15.4%
23.84%
25.77%
18.08%
See all

  • Gainers

  • Losers

Top Growth Drivers
1M Return
Blue Jet Healthcare Ltd
Blue Jet Healthcare Ltd
31.9%
Ami Organics Ltd
Ami Organics Ltd
8.5%
Navin Fluorine International Ltd
Navin Fluorine International Ltd
7.1%
Fund
Jan'25
Dec'24
Nov'24
No of Holdings
55
53
50
Top 5 Company Concentration
35.4%
30.7%
27.6%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (10.3%)
Sun Pharmaceuticals Industries Ltd (8.9%)
Sun Pharmaceuticals Industries Ltd (9.5%)
No of Sectors
3
3
3
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (95.4%)
Health (95.1%)
Health (95%)
Loading...
We are taking more time than usual
Piyush Baranwal
Piyush Baranwal
Fund Manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, since 6 February 2024
Top funds managed
Scheme
Annualised Returns(3Y)
Category Returns(3Y)
WhiteOak Capital Special Opportunities Fund Direct Growth
0%
--
Whiteoak Capital Large & Mid Cap Fund Direct Growth
0%
15.96%
WhiteOak Capital Ultra Short Duration Fund Direct Growth
6.54%
6.17%
Fund House
WhiteOak Capital Asset Management Limited
Total Schemes
19
See all WhiteOak schemes
Total AUM
₹16.43K Cr
as on 31-Jan-2025
Address
602B, 6th Floor,Indiabulls Finance Centre(IFC),1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City
Phone
+91180030003060
Website
http://mf.whiteoakamc.com

WhiteOak Capital Pharma and Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 24.57% since inception which is more than its category average return of 16.97%
Fund Allocations

Fund Allocations

This fund has an allocation of 92.28% in Equity, 0% in Debt and 7.72% in Cash related instruments
AUM size ₹286 Cr

AUM size ₹286 Cr

This fund has AUM of ₹286 Cr which is less than its category average of ₹ 1838 Cr
Expense Ratio 0.68%

Expense Ratio 0.68%

This fund has an expense ratio of 0.68% which is less than its category average expense ratio of 1.43%

Frequently Asked Questions for WhiteOak Capital Pharma and Healthcare Fund Direct Growth

The current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is ₹12.38 as on 21-Feb-2025.
Existing (Absolute + CAGR) as on 21-Feb-2025.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
-6.24%
-6.24%
6 Month Returns
3.13%
3.13%
1 Year Returns
23.98%
23.98%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.68% as on January 2025
₹286 Cr as on January 2025
Sun Pharmaceuticals Industries Ltd(10.33%), Cipla Ltd(7%), Max Healthcare Institute Ltd Ordinary Shares(6.93%), Divi's Laboratories Ltd(6.18%), Lupin Ltd(4.95%) as on January 2025
Health(88.01%), Basic Materials(3.76%), Financial Services(0.5%) as on January 2025
The alpha ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
-
-
-
As on January 2025
The alpha for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
-
-
-
As on January 2025
The Beta for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
-
-
-
As on January 2025
The sharpe ratio for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
-
-
-
As on January 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Piyush Baranwal is the fund manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth
The Exit load of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is 1%